News & Events

Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Today, March 9, 2026 , West Pharmaceutical Services, Inc. (the “Company”) announced that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth…

Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference. A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference. The information in this report (including the exhibits attached hereto) is being furnished pursuant to

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Today, September 11, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Kimberly Banks MacKay, Senior Vice President, General Counsel, and Corporate Secretary, will be leaving the Company. The Company and Ms. MacKay have agreed to discuss an appropriate transition period which will end no later than December 31, 2025, to ensure…

of a Current Report on Form 8-K as in effect on the date of this Agreement pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, (the “Act”), provided, that, without limitation, a Change in Control shall be deemed to have occurred if: (i) Any Person, other than: (1) the Company, (2) any Person who on the date hereof is a director or officer of the Company, or (3) a trustee or fiduciary holding securities under an employee benefit plan of the Company, is or become…

of Form 8-K or other information “furnished” to the Commission) by reference in this Participant Information Statement and to be a part hereof from the date of filing of such documents. Upon written or oral request, you can obtain a copy of any of the following documents: (i) Any of the documents incorporated herein by reference; (ii) The Company’s Annual Report to Shareholders for its latest fiscal year; and (iii) Any or all reports, proxy statements and other communications distributed to s…

on a Form 8-K. In addition, a change in control includes a change within a 2 year period in the majority of our Board of Directors that was not approved in advance by existing directors. A change in control also occurs if an entity (with certain exceptions) becomes the beneficial owner of more than 50% of the combined voting power of our securities or if the shareholders approve a plan of complete liquidation, an agreement for the sale or disposition of all or substantially all of the Company…

of a Current Report on Form 8-K as in effect on the date of this Agreement pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, (the “Act”), provided, that, without limitation, a Change in Control shall be deemed to have occurred if: (i) Any Person, other than: (1) the Company, (2) any Person who on the date hereof is a director or officer of the Company, or (3) a trustee or fiduciary holding securities under an employee benefit plan of the Company, is or become…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, has departed the Company, effective the same day. As part of this transition, her leadership responsibilities will be managed on an interim basis by Aileen Kinsella, the Company's Head of Proprie…

Other Events. On December 9, 2024, the Board of Directors approved a share repurchase program authorizing the repurchase of up to 550,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. This share repurchase program is expected to be completed by December…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 1, 2024, Silji Abraham, Senior Vice President & Chief Technology Officer of West Pharmaceutical Services, Inc. (the “Company”), notified the Company that he intends to resign, effective December 31, 2024, to pursue other interests. The Company will work with Mr. Abraham and his leadership team to ensure a smooth transition of his duties…

Departure of Directors or Certain Officers; Election of Directors; Appointments of Certain Officers; Compensatory Arrangements of Certain Officers. On April 26, 2024, West Pharmaceutical Services, Inc. (“West”) announced an update to the role of Bernard Birkett, Chief Financial and Operations Officer. Since May 2022, Mr. Birkett served as both our Principal Financial and Principal Operating Officer. Mr. Birkett‘s leadership while in this combined role has greatly enhanced the operations capab…